<DOC>
	<DOC>NCT02266537</DOC>
	<brief_summary>The study was aimed to evaluate the pharmacological effect of different α-antagonists on phenylephrine induced pupil size in healthy male volunteers as pharmacological basis for Intraoperative floppy iris syndrome (IFIS)</brief_summary>
	<brief_title>Study to Assess the Influence of Three Different α-antagonists and Placebo on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Mydriasis</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Doxazosin</mesh_term>
	<mesh_term>Alfuzosin</mesh_term>
	<mesh_term>Phenylephrine</mesh_term>
	<mesh_term>Oxymetazoline</mesh_term>
	<criteria>Healthy male Age ≥ 21 and ≤ 55 years Body Mass Index (BMI) ≥ 18.5 and ≤ 29.9 kg/m2 Signed and dated written informed consent in accordance with Good Clinical Practice (GCP) and local legislation Any finding of the medical examination (including blood pressure, pulse rate and Electrocardiogram (ECG)) deviating from normal and of clinical relevance Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders History of orthostatic hypotension, fainting spells or blackouts Chronic or relevant acute infections History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator Intake of drugs with a long halflife (&gt; 24:00 hours) within at least one month or less than ten halflives of the respective drug before enrolment in the study or during the study Use of any drugs which might influence the results of the trial up to seven days prior to enrolment in the study or during the study Participation in another trial with an investigational drug (≤ two months prior to administration or during the trial) Smoker (&gt; 10 cigarettes or &gt; 3 cigars or &gt; 3 pipes/day) Inability to refrain from smoking on inhouse trial days Alcohol abuse (&gt; 60 g/day) Drug abuse Blood donation (≥ 100 mL within four weeks prior to administration or during the trial) Any laboratory value outside the clinically accepted reference range Excessive physical activities within the last week before the trial or during the trial The following exclusion criteria are of special interest for this study: Hypersensitivity to any alpha agonist, or to phenylephrine Supine blood pressure at screening of systolic &lt; 110 mmHg and diastolic &lt; 60 mmHg Ophthalmological criteria: Corrected visual acuity &lt; 0.5 Refractive Error with a spherical equivalent &gt; +6 or smaller 6 D Elevated intraocular pressure (higher than 22 mmHg) Relevant anisocoria or pupil deformation History of eye surgery apart from laser trabeculoplasty less than three months previously or extraocular surgery such as strabismus surgery Topical ocular medication influencing IOP (intraocular pressure) or pupil size within 3 months prior to studystart</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>